Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 892 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Comparator Condition Clear all
Completed Phase 2 Interventional

Mobile Technology and Online Tools to Improve Asthma Control in Adolescents

NCT02835300
View directory record Official record
Conditions
Asthma
Interventions
CampAir, Information and Referral
Behavioral
Lead sponsor
3-C Institute for Social Development
Industry
Eligibility
13 Years to 18 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 25, 2026, 2:04 AM EDT
Terminated Phase 2 Interventional

A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.

NCT03196375
View directory record Official record
Conditions
Motor Neuron Disease
Interventions
FLX-787-ODT (orally disintegrating tablet), Placebo ODT
Drug
Lead sponsor
Flex Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Scottsdale, Arizona • Sacramento, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 25, 2026, 2:04 AM EDT
Recruiting Not applicable Interventional

Sleep and Light Intervention (SALI) for Menopausal Mood Dysfunction

NCT06678880
View directory record Official record
Conditions
Depression, Depression During the Menopausal Transition, Menopausal Depression
Interventions
Phase Advanced Intervention (PAI), Phase Delay Intervention (PDI)
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 25, 2026, 2:04 AM EDT
Terminated Phase 2 Interventional Results available

Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease

NCT02824913
View directory record Official record
Conditions
Dry Eye Disease
Interventions
P-321 Ophthalmic Solution, P-321 Ophthalmic Solution placebo
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Plantation, Florida
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 25, 2026, 2:04 AM EDT
Recruiting Phase 1 Interventional

Islet Function in Gestational Diabetes

NCT07806695
View directory record Official record
Conditions
Gestational Diabetes Mellitus
Interventions
Exendin 9-39
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 25, 2026, 2:04 AM EDT
Completed Not applicable Interventional

Interactive Multirisk-Factor Intervention for Hypertension (HTN) Blacks

NCT00207194
View directory record Official record
Conditions
Hypertension
Interventions
Automated Telephone Program, Health Behavior Education
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
35 Years and older
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 25, 2026, 2:04 AM EDT
Recruiting Phase 3 Interventional

Shingrix in Renal Transplant Recipients

NCT04128189
View directory record Official record
Conditions
Kidney Transplant Recipient Response to Shingrix Vaccine, Kidney Failure, Kidney Failure, Chronic, Kidney Transplantation, Herpes Zoster (HZ)
Interventions
Shingrix
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
4
States / cities
Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 25, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Propranolol Hydrochloride 160 mg Tablets Under Fasting Conditions

NCT00865215
View directory record Official record
Conditions
Healthy
Interventions
Propranolol Hydrochloride Extended Release Capsules 160 mg, INDERAL® LA 160 mg Capsules, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 25, 2026, 2:04 AM EDT
Completed Phase 3 Interventional Results available

Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT00360555
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological
Interventions
flibanserin, flibanserin 50mg, flibanserin 100mg, placebo
Drug
Lead sponsor
Sprout Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
1,584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
64
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Oct 25, 2026, 2:04 AM EDT
Completed Phase 3 Interventional Results available

Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder

NCT03078075
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Naltrexone: Vivitrol®, Placebo (PLB) Injectable, Bupropion: Wellbutrin XL®, Placebo (PLB) Oral
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 25, 2026, 2:04 AM EDT
Completed Phase 2 Interventional Results available

Enhancing the Effects of Alcohol Treatment With Lamotrigine

NCT04770493
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Lamotrigine, Placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
16 Years to 24 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 25, 2026, 2:04 AM EDT
Completed Phase 3 Interventional

A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)

NCT05428033
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
centanafadine capsule, placebo capsule
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
4 Years to 12 Years
Enrollment
574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 25, 2026, 2:04 AM EDT
Terminated Phase 3 Interventional Results available

A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension

NCT03323749
View directory record Official record
Conditions
Primary Mitochondrial Myopathy
Interventions
elamipretide, placebo comparator, elamipretide open label treatment
Combination Product
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
16 Years to 80 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
La Jolla, California • Palo Alto, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 25, 2026, 2:04 AM EDT
Recruiting Phase 1 Interventional

Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation

NCT07076498
View directory record Official record
Conditions
Glioma
Interventions
M032
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
36 Months and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 25, 2026, 2:04 AM EDT
Completed Phase 2 Interventional Results available

A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)

NCT04944992
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Interventions
Efinopegdutide 20 mg/mL, Semaglutide 1.34 mg/mL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Montclair, California • Hialeah, Florida • Miami Lakes, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 25, 2026, 2:04 AM EDT
Completed Not applicable Interventional

Psychotherapy for PTSD Among Veterans Also Receiving Drug or Alcohol Treatment

NCT04581434
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, Substance Use Disorders
Interventions
Prolonged Exposure Therapy, Cognitive Processing Therapy, Present Centered Therapy
Behavioral
Lead sponsor
Center for Veterans Research and Education
Other
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
14
States / cities
San Diego, California • Tampa, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 25, 2026, 2:04 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Pork Protein on Recovery Following Simulated Fireground Activity

NCT07819565
View directory record Official record
Conditions
Exercise Recovery, Physical Performance Parameters, Muscle Damage, Cognition, Blood Biomarkers, Stress
Interventions
Pork-Based Protein Ready-to-Eat Meals, Plant-Based Protein Ready-to-Eat Meals, Carbohydrate-Focused Lower-Protein Ready-to-Eat Meals
Other
Lead sponsor
Sam Houston State University
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Fort Worth, Texas • Huntsville, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 25, 2026, 2:04 AM EDT
Active, not recruiting Not applicable Interventional

Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial

NCT05925634
View directory record Official record
Conditions
Myocardial Infarction, Coronary Artery Bypass, Percutaneous Coronary Intervention, Heart Failure, Cardiac Valve Surgery
Interventions
RPE (usual care), GXT+THHR (intervention)
Behavioral
Lead sponsor
Baystate Medical Center
Other
Eligibility
60 Years to 99 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Springfield, Massachusetts • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 25, 2026, 2:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.

NCT00784719
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
CP-690,550, Cyclosporine, CP-690,550 Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
27
States / cities
Chandler, Arizona • Peoria, Arizona • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Oct 25, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fed Conditions

NCT00865371
View directory record Official record
Conditions
Healthy
Interventions
Abrika Bupropion 150 mg Extended-Released Tablet, Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Oct 25, 2026, 2:04 AM EDT
Completed Phase 2 Interventional

Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease

NCT01850381
View directory record Official record
Conditions
Parkinson's Disease
Interventions
GM608, Placebo Comparator
Drug
Lead sponsor
Genervon Biopharmaceuticals, LLC
Industry
Eligibility
30 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 25, 2026, 2:04 AM EDT
Completed Phase 4 Interventional Results available

A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease

NCT01485172
View directory record Official record
Conditions
Parkinson Disease
Interventions
ropinirole monotherapy, placebo monotherapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
11
States / cities
Fountain Valley, California • Pasadena, California • Reseda, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 25, 2026, 2:04 AM EDT
Completed Phase 2 Interventional Results available

A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease

NCT06001177
View directory record Official record
Conditions
Celiac Disease, Coeliac Disease
Interventions
KAN-101, Placebo
Drug
Lead sponsor
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Colorado Springs, Colorado • Hialeah Gardens, Florida • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 25, 2026, 2:04 AM EDT